YHR145C Antibody

What is YHR145C Antibody and what organism is it reactive against?

YHR145C Antibody is a polyclonal antibody raised in rabbits against recombinant Saccharomyces cerevisiae (strain ATCC 204508/S288c, commonly known as Baker's yeast) YHR145C protein. It specifically reacts with Saccharomyces cerevisiae proteins and has been affinity-purified to ensure high specificity. This antibody is designed for research applications and targets the YHR145C protein (UniProt: O13537) .

What is the optimal storage condition for YHR145C Antibody to maintain functionality?

The YHR145C Antibody should be stored at -20°C or -80°C upon receipt. The antibody is supplied in liquid form containing preservative (0.03% Proclin 300) and constituents (50% Glycerol, 0.01M PBS, pH 7.4) that help maintain stability. Importantly, researchers should avoid repeated freeze-thaw cycles as this can lead to protein denaturation and loss of antibody function. For projects requiring multiple uses, it is recommended to prepare small aliquots before freezing to minimize freeze-thaw damage .

What applications has the YHR145C Antibody been validated for?

The YHR145C Antibody has been tested and validated for ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot (WB) applications to ensure identification of the target antigen. These validation studies confirm the antibody's suitability for detecting the YHR145C protein in these specific applications. Researchers should note that optimization might be required when using this antibody in other immunological techniques not explicitly listed in the product specifications .

How should I optimize Western Blot protocols when using YHR145C Antibody?

When optimizing Western Blot protocols with YHR145C Antibody, start with these methodological considerations:

• Sample preparation: Ensure proper lysis of yeast cells using glass beads or enzymatic methods optimized for yeast cell walls

• Protein loading: Begin with 20-50 μg of total protein per lane

• Blocking: Use 5% non-fat dry milk or BSA in TBST (Tris-buffered saline with 0.1% Tween-20)

• Primary antibody dilution: Start with a 1:1000 dilution and adjust based on signal intensity

• Incubation: Overnight at 4°C for primary antibody is recommended for optimal binding

• Controls: Include wild-type and YHR145C knockout samples when possible to validate specificity

This approach mirrors optimization strategies used for other yeast antibodies in similar experimental contexts .

What controls should be included when using YHR145C Antibody in ELISA assays?

For ELISA applications with YHR145C Antibody, implement these essential controls:

• Positive control: Purified recombinant YHR145C protein

• Negative control: Lysate from YHR145C deletion strain

• Antibody specificity control: Pre-absorption of antibody with excess antigen

• Secondary antibody control: Wells with no primary antibody to assess non-specific binding

• Background control: Wells with no antibodies or antigen

These controls help distinguish specific signals from background and enable proper data interpretation, similar to control strategies employed in antibody binding studies for other organisms .

How can I determine the appropriate dilution of YHR145C Antibody for my specific experiment?

To determine the optimal dilution for YHR145C Antibody:

• Perform a titration experiment using serial dilutions (e.g., 1:500, 1:1000, 1:2000, 1:5000)

• For Western blots, analyze signal-to-noise ratio at each dilution

• For ELISA, generate a standard curve with known concentrations of the target protein

• Select the dilution that provides clear specific signal with minimal background

• Validate the chosen dilution across multiple experimental replicates

This approach allows optimization while conserving antibody and follows standard immunoassay development principles seen in other antibody validation studies .

How can I reduce non-specific binding when using YHR145C Antibody?

To minimize non-specific binding with YHR145C Antibody:

• Increase blocking agent concentration (try 5-10% BSA or non-fat dry milk)

• Add 0.1-0.5% Tween-20 to washing and antibody dilution buffers

• Pre-absorb the antibody with lysate from non-target species

• Reduce primary antibody concentration if high background persists

• Increase washing duration and number of washes (minimum 3x10 minutes)

• For yeast samples, pre-clear lysates by centrifugation to remove cell debris

These techniques mirror approaches used successfully with other polyclonal antibodies to improve signal specificity in complex samples .

What are potential causes for weak or absent signal when using YHR145C Antibody?

If experiencing weak or absent signals with YHR145C Antibody, systematically investigate these potential causes:

• Protein expression levels: YHR145C may be expressed at low levels under standard conditions

• Protein extraction efficiency: Yeast cell walls can hinder complete protein extraction

• Epitope masking: Post-translational modifications or protein interactions may block antibody binding

• Antibody degradation: Improper storage or excessive freeze-thaw cycles may reduce activity

• Procedural issues: Inadequate transfer in Western blots or inefficient coating in ELISA

• Detection system sensitivity: Consider using enhanced chemiluminescence or amplification systems

This troubleshooting approach parallels methods used for other challenging antibody applications in yeast systems .

How can I evaluate cross-reactivity of YHR145C Antibody with related proteins?

To assess potential cross-reactivity of YHR145C Antibody:

• Perform sequence homology analysis to identify proteins with similar epitope regions

• Test the antibody against recombinant proteins with structural similarity to YHR145C

• Use knockout/knockdown validation to confirm signal specificity

• Conduct immunoprecipitation followed by mass spectrometry to identify all bound proteins

• Compare reactivity patterns across different yeast strains or related species

This multi-faceted approach provides rigorous validation similar to methods used for antibody characterization in other research contexts .

How does antibody batch variation impact experimental reproducibility with YHR145C Antibody?

To address batch variation concerns with YHR145C Antibody:

• Maintain internal reference standards to compare batch performance

• Perform side-by-side validation when transitioning to a new lot

• Document lot-specific optimal dilutions and performance characteristics

• Consider pooling antibody from multiple production lots for long-term studies

• Implement standardized quality control metrics for each new batch

Such standardization approaches are critical for maintaining experimental reproducibility, especially for made-to-order antibodies with potentially variable characteristics .

What strategies can be employed to enhance detection sensitivity for low-abundance YHR145C protein?

For enhanced detection of low-abundance YHR145C protein:

• Implement targeted protein enrichment through subcellular fractionation

• Use signal amplification systems like tyramide signal amplification in immunodetection

• Apply proximity ligation assays for increased sensitivity

• Consider sample concentration methods like immunoprecipitation before detection

• Optimize cell growth conditions to increase target protein expression

• Use more sensitive detection methods like ECL-Plus or fluorescent secondary antibodies

These approaches mirror advanced detection strategies used in studies of other low-abundance yeast proteins .

How can YHR145C Antibody be incorporated into multiplexed detection systems?

For multiplexed detection incorporating YHR145C Antibody:

• Select compatible primary antibodies from different host species

• Use secondary antibodies with distinct fluorophores or enzyme conjugates

• Implement sequential detection protocols with thorough stripping between rounds

• Consider microarray-based detection systems for high-throughput applications

• Validate antibody performance in multiplex format compared to single-plex detection

• Assess for potential interference between detection systems

This methodology aligns with contemporary approaches for studying multiple targets simultaneously in complex biological systems .

How can I design experiments to account for maternal antibody interference when using YHR145C Antibody?

When designing experiments where maternal antibody interference is a concern:

• Quantify pre-existing antibody levels in samples before immunization or challenge

• Establish baseline correlations between maternal antibody titers and experimental outcomes

• Include stratified analysis based on pre-existing antibody levels

• Consider timing adjustments to allow for maternal antibody decay

• Implement statistical approaches to control for maternal antibody as a covariate

This approach draws on principles used to address maternal antibody interference in immunization studies, which can be adapted to research with YHR145C Antibody in certain experimental contexts .

What active learning strategies can improve experimental efficiency when working with YHR145C Antibody?

To implement active learning strategies with YHR145C Antibody:

• Start with small-scale pilot experiments to identify optimal conditions

• Use factorial design to simultaneously test multiple parameters

• Implement iterative experimental approaches where each round informs the next

• Apply machine learning algorithms to predict optimal conditions based on initial data

• Utilize library-on-library approaches when screening multiple variants or conditions

These approaches have been shown to reduce experimental costs by up to 35% and accelerate research progress compared to traditional methods in antibody studies .

How should I interpret conflicting results from different immunoassays using YHR145C Antibody?

When faced with conflicting results across immunoassays:

• Evaluate assay-specific limitations (sensitivity, specificity, dynamic range)

• Consider epitope accessibility differences between methods (native vs. denatured)

• Assess potential interference from sample components in each assay format

• Implement orthogonal validation using non-antibody-based methods

• Reconcile conflicts through comprehensive controls and method optimization

• Document methodological details that might contribute to discrepancies

This systematic approach to data interpretation reflects best practices in antibody-based research where multiple detection methods may yield apparently contradictory results .